© 2026 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 161 Farringdon Rd, London EC1R 3AL. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions | Cookies

SRI

Top section

Top section

Canaries defies Spanish supply run with debut sustainable bond

◆ Island region prices €500m sustainable 10 year ◆ Spread tightened 5bp from guidance after book grew ◆ Banker away from deal sees no congestion drag
FIG
◆ First deal to release IPTs on busy day ◆ MPS M&A bid had 'no impact' on deal, says lead ◆ Priced flat to fair value

My start-up is a let-down

I thought the grass would be greener in fintech land, but it’s patchy and dreary

Snam takes €1.5bn with EuGB and SLB pair

◆ Italian issuer pairs two sustainable formats ◆ Trade hits size targets ◆ Tight price tests investors' limits
FIG
◆ First deal to release IPTs on busy day ◆ MPS M&A bid had 'no impact' on deal, says lead ◆ Priced flat to fair value
Sub-sections
  • The Ivory Coast sought to raise some extra euro cash by tapping bonds in euros on Monday but, with two African sovereigns requesting debt restructuring support from the G20 over the last week, some market participants have begun to question the continent's borrowers.
  • Zambia, which months ago became Africa’s first sovereign default since the pandemic started, has requested debt treatment under the G20’s Common Framework. That makes it the third African sovereign to request restructuring support under the guidelines, which were first announced in November.
  • Huge demand for exposure to biotech companies among US equity investors is continuing to drive UK firms to list on the other side of the Atlantic through an IPO on the Nasdaq. On Thursday, Immunocore, a late-stage biotech firm focused on T-cell technology, priced an enlarged offering on the exchange and, on Friday, UK healthcare investor Syncona announced it was exploring a US IPO for one of its portfolio companies.